• GSK and Alector announce global collaboration in immuno-neurology worldpharmanews
    July 05, 2021
    GlaxoSmithKline plc and Alector, announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
PharmaSources Customer Service